comparemela.com

Ricardos Pacheco News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |PAION AG Announcements | PAION AG: PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL

Investegate announcements from PAION AG, PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL

United statesUnited kingdomSouth koreaMinas geraisGregor siebertProdutos quimicos farmaceuticos ltdaRalf pennerRicardos pachecoBrazilian health regulatory agencyFrankfurt stock exchangeInvestor relations corporate communicationsPrime standardLatin americanNew drug applicationLatin americaInvestegate announcements

EQS-News: PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL

EQS-News: PAION AG / Key word(s): Regulatory Admission PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICE.

United statesUnited kingdomSouth koreaMinas geraisGregor siebertProdutos quimicos farmaceuticos ltdaRalf pennerRicardos pachecoBrazilian health regulatory agencyFrankfurt stock exchangeInvestor relations corporate communicationsPrime standardLatin americanNew drug applicationLatin americaVice president investor relations

Investegate |PAION AG Announcements | PAION AG: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA

Investegate announcements from PAION AG, PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA

United statesUnited kingdomSouth koreaMinas geraisProdutos quimicos farmaceuticos ltdaRalf pennerJim phillipsRicardos pachecoFrankfurt stock exchange prime standardDistribution servicesNew drug applicationLatin americaLatin americanRegulatory announcementsCorporate newsInvestegate announcements

DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA

DGAP-Ad-hoc: PAION AG / Key word(s): Contract PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMA.

United statesUnited kingdomSouth koreaMinas geraisProdutos quimicos farmaceuticos ltdaRalf pennerJim phillipsRicardos pachecoFrankfurt stock exchange prime standardDistribution servicesNew drug applicationLatin americaLatin americanRegulatory announcementsCorporate news

PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA

27.04.2022 PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA | PAION AG | News | Nachricht | Mitteilung

United statesUnited kingdomSouth koreaMinas geraisProdutos quimicos farmaceuticos ltdaRalf pennerJim phillipsRicardos pachecoFrankfurt stock exchange prime standardDistribution servicesNew drug applicationLatin americaLatin americanRegulatory announcementsCorporate newsD hoc

vimarsana © 2020. All Rights Reserved.